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S-palmitoylation represents a novel mechanism
regulating the mitochondrial targeting of BAX and
initiation of apoptosis
M Fro¨hlich1, B Dejanovic1, H Kashkar2, G Schwarz*,1 and S Nussberger*,1,3
The intrinsic pathway of apoptotic cell death is mainly mediated by the BCL-2-associated X (BAX) protein through
permeabilization of the mitochondrial outer membrane (MOM) and the concomitant release of cytochrome c into the cytosol. In
healthy, non-apoptotic cells, BAX is predominantly localized in the cytosol and exhibits a dynamic shuttle cycle between the
cytosol and the mitochondria. Thus, the initial association with mitochondria represents a critical regulatory step enabling BAX
to insert into MOMs, promoting the release of cytochrome c and ultimately resulting in apoptosis. However, the molecular mode
of how BAX associates with MOMs and whether a cellular regulatory mechanism governs this process is poorly understood.
Here we show that in both primary tissues and cultured cells, the association with MOMs and the proapoptotic action of BAX is
controlled by its S-palmitoylation at Cys-126. A lack of BAX palmitoylation reduced BAX mitochondrial translocation, BAX
oligomerization, caspase activity and apoptosis. Furthermore, ectopic expression of specific palmitoyl transferases in cultured
healthy cells increases BAX S-palmitoylation and accelerates apoptosis, whereas malignant tumor cells show reduced BAX
S-palmitoylation consistent with their reduced BAX-mediated proapoptotic activity. Our findings suggest that S-palmitoylation of
BAX at Cys126 is a key regulatory process of BAX-mediated apoptosis.
Cell Death and Disease (2014) 5, e1057; doi:10.1038/cddis.2014.17; published online 13 February 2014
Subject Category: Cancer
Intrinsic apoptotic signaling converges on BCL-2-associated X
protein (BAX), which drives the mitochondrial outer membrane
permeabilization (MOMP) in the majority of cells.1–7 Failure in
regulating this process can lead to distinct autoimmune
diseases,8 cancer9–11 and neurodegenerative disorders.12–14
During apoptosis BAX is inserted in the mitochondrial outer
membrane (MOM) by a C-terminal tail anchor (TA).1 TA
confers the association of cellular proteins mainly with the
endoplasmic reticulum or mitochondria, where they are
inserted into the lipid membrane via a single membrane
span.15 Unlike the majority of TA proteins, including anti-
apoptotic Bcl-2 family members Bcl-2 and Bcl-xL and the
proapoptotic Bcl-2 family member BAK that are constitutively
bound to their target membranes including mitochondrial
and/or ER membranes, BAX in its monomeric inactive state
predominantly appears in the cytosol of non-apoptotic cells.16
The solubility of BAX is effectively regulated by the reduced
exposure of its hydrophobic C terminus17 consistent with its
predominantly cytosolic distribution in non-apoptotic cells,
whereas only a minor fraction of BAX has been shown to
be loosely attached to MOMs.18 Recent data conclusively
showed that BAX exists in dynamic equilibrium between the
cytosolic and mitochondrial compartment.18
Following apoptotic stimuli, BAX undergoes a conforma-
tional change to expose the reactive BH3 domain for dimer
formation and to disengage the transmembrane anchor (TA)
from the protein core, which in turn promotes its MOM
insertion.17,19 In particular, the dimer formation via the BH3
domain has been shown to be facilitated in the presence of
lipids,7 implying that the initial mitochondrial association of
BAX provides a prerequisite for its subsequent activation by
BH3 domain binding. However, the underlying molecular
mechanism governing the dynamic and reversible equilibrium
between cytosolic and mitochondrial BAX is largely unknown.
The structural and functional related proapoptotic BCL-2
protein BID exhibits striking similarities to BAX including the
translocation to the MOM. In their inactive state both proteins
show a predominantly cytosolic localization and accumulate
at the mitochondria upon apoptosis induction. It was shown
that BID acquires the affinity for MOM after its cleavage
by caspase-8 via a unique lipid modification, namely a
post-translational myristoylation.20 As BAX unlike BID lacks
a canonical consensus motif for myristoylation as well as
the necessary N-terminal glycine, we asked whether
S-palmitoylation at a cysteine residue could mediate the
translocation of BAX to the outer mitochondrial membrane.
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Protein S-palmitoylation represents a unique lipid
modification process mediated by members of the palmitoyl-
transferase family. S-palmitoylation serves as a reversible
post-translational process mediating membrane targeting of
various proteins. In particular, for proteins containing trans-
membrane segements,21–25 S-palmitoylation is suggested to
change the tilt of the transmembrane segments within the
bilayer or alter its conformation,26 thereby promoting protein–
protein interaction and complex formation.25,27–29 On the
basis of its ability to control the distribution and the function of
a number of transmembrane- and membrane-associated
proteins (e.g. associated with ER), here we asked whether
S-palmitoylation of BAX could impact on the molecular switch
regulating the dynamic and reversible equilibrium between
cytosolic and mitochondrial BAX.
Our data show that a single cysteine residue in BAX is
S-palmitoylated in tissue extracts and cell culture. Failure of
BAX S-palmitoylation causes lack of BAX oligomerization,
mitochondrial targeting and apoptosis. Congruently,
enhanced S-palmitoylation of BAX by ectopic expression of
distinct palmitoyl acyltransferases in cells increased sensitiv-
ity to apoptosis. By using malignant tumor cells derived from
Hodgkin lymphoma (HL) patients, we highlight the lack of BAX
S-palmitoylation as an underlying molecular mechanism how
these tumor cells resist apoptosis.30 This new mechanism
may open up new avenues toward our understanding in the
regulation of BAX subcellular distribution and consequently its
apoptotic activity.
Results
BAX is S-palmitoylated in tissue extracts and cell
culture. To elucidate the molecular mechanism controlling
the transit of BAX to and from mitochondria in response to
apoptotic stimuli, we investigated lipid modification of BAX
and used acyl biotin-exchange (ABE) chemistry.31 Probing
equivalent amounts of protein with BAX-specific antibodies
revealed endogenous S-palmitoylated BAX protein in the
brain, liver, lung, spleen, testis and kidney (Figure 1a), in
human embryonic kidney 293 (HEK293) cells and in
fibroblast-like green monkey kidney cells (Cos7) (Figure 1b).
We further found palmitoylation of BAX in Sf9 insect cells
following recombinant expression of human BAX (Figure 1b).
Treatment of HEK293 cells with 2-bromopalmitate, a
competitive inhibitor of protein acyltransferases, was found
to reduce S-palmitoylation of endogenous BAX (Figure 1c).
To further validate our findings, we performed 3H-palmitate
incorporation experiments upon ectopic expression of BAX in
Sf9 cells. Metabolic radiolabeling of BAX was shown by
autoradiography (Figure 1d). These results demonstrate that
BAX is post-translationally S-palmitoylated, both in native
tissues and cell culture.
To determine which residues of BAX are palmitoylated, we
generated BAX variants in which Cys-62 and Cys-126,
the only two cysteine residues and potential sites of
S-palmitoylation, were replaced by serine. Variants were
expressed with a C-terminal MYC epitope tag to allow
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Figure 1 S-palmitoylation of BAX in mouse tissues and cultured cells. (a) Protein extracts from mouse tissues were tested for S-palmitoylated BAX following the ABE.
Biotinylated proteins were purified, separated (by SDS-PAGE) and stained with anti-BAX antibodies (a-BAX). Biotinylation of BAX is prominent in protein extracts that were
treated with hydroxylamine (HA); n¼ 2. (b) S-Palmitoylation of BAX in HEK293 and Cos7 cells as well as SF9 cells expressing human BAX using the ABE; n¼ 2. (c) Inhibition
of protein acyltransferase for 16 h by 2-bromopalmitate (2-BP) reduce BAX palmitoylation in HEK293 cells as shown by ABE. Quantification of relative amounts of
palmitoylated BAX is shown. Error bars±S.E.M.; n¼ 6; **Po0.01. Input in panels (a–c) were 10% of total protein extract; P.d., pull down: protein bound to affinity resin.
(d) Radiolabeling of BAX with 3H-palmitic acid (3H-PA). SF9 cells expressing for 48 h human His-tagged BAX were subsequently incubated with 3H-PA for 12 h. BAX was
isolated using Ni-affinity chromatography, run on SDS-PAGE and visualized either by silver staining or autoradiography
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unambiguous identification of exogenous BAX in cultured
cells. Following transient expression in HEK293 cells, BAX
was assayed for S-palmitoylation. Western blot analysis of
protein extracts from cells expressing MYC-tagged wild-type
(WT) and C62S BAX variants revealed two forms of BAX, the
full-length 21 kDa protein and a fragment with an approximate
molecular mass of 18 kDa (Figure 2a), both of which were
S-palmitoylated. By contrast, protein lysates from cells
expressing the BAX C126S variant showed only a 21 kDa
band in the input and loss of the S-palmitoylation signal
(Figure 2a). We conclude that S-palmitoylation of BAX occurs
on residue Cys-126. The 18 kDa fragment likely represents
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Figure 2 S-palmitoylation influences oligomerization and subcellular localization of BAX. (a) S-palmitoylation of MYC-tagged human BAX, BAX C62S or BAX C126S;
n¼ 3. Input, 10% of total protein extract; P.d., pull down, HA, hydroxylamine. (b) BAX oligomerization in HEK293 cells expressing MYC-tagged WT, C62S and C126S BAX
analyzed by size-exclusion chromatography, followed by immunoblotting of fractions with anti-MYC antibodies. Thy, thyroglobulin (669 kDa); Fer, ferritin (440 kDa); Ova,
ovalbumin (44 kDa); Sma, SMAC (25 kDa). (c) Mitochondria from HEK293 cells expressing C terminally MYC-tagged WT BAX, BAX C62S and BAX C126S, analyzed by
immmunoblotting with anti-BAX or anti-MYC antibodies. VDAC, mitochondrial (Mt) marker. Bars (mean±S.E.M.; n¼ 4; **Po0.01) show quantification of relative amounts of
mitochondrial BAX. Cyt, cytosol. (d) Cos7 cells transiently expressing WT and mutant BAX, N terminally fused with EGFP, were examined by microscopy for BAX clusters.
Mitochondria were labeled with MitoTracker, nuclei with bisbenzimide. Number of cells with small punctate structures was quantified. Error bars±S.E.M.; n¼ 6; ***Po0.001,
Bars, 10mm. (e) S-palmitoylated BAX copurifies with mitochondria isolated from HEK293 cells, transfected with Golgi marker (ECFP-GT). Proteins present in the Golgi/ER
(Golg/ER) and mitochondrial fraction (Mt) were tested for palmitoylated BAX using ABE. VDAC, Calnexin and EGFP-GT were probed as markers for the respective fractions
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p18BAX, which is derived from full-length BAX via proteolytic
cleavage following the initiation of apoptosis,32 a process that
appeared to be absent or strongly reduced in BAX C126S.
S-palmitoylation influences oligomerization and sub-
cellular localization of BAX. Given that the formation of
higher-order oligomers is a prerequisite in BAX-mediated
MOMP,33 we next investigated oligomer formation and the
subcellular localization of BAX variants. Crude cell protein
extracts of HEK293 cells expressing either WT, C62S or
C126S BAX variants were clarified and separated by size-
exclusion chromatography (Figure 2b). Consistent with
previous work,34 WT BAX eluted from the column in two
separate fractions corresponding to BAX monomers of
B20 kDa and BAX oligomers larger than 400 kDa. Although
BAX C62S showed the same elution as WT BAX, BAX
C126S was found primarily in the 20 kDa fraction, indicating
that the single C126S exchange reduced the propensity of
BAX to form higher-order oligomers.
We next isolated mitochondria from HEK293 cells expres-
sing either N terminally EGFP-tagged or C terminally MYC-
tagged WT, C62S or C126S BAX variants and detected them
by western blot analysis using either anti-BAX or anti-MYC
antibodies, respectively. In contrast to mitochondria from cells
expressing WT or C62S BAX variants, which showed a strong
BAX signal, only trace amounts of BAX C126S variant were
found in the mitochondria (Figure 2c), whereas the mitochon-
drial marker VDAC was equally distributed. Cytosolic
BAX was found with all three variants (Figure 2c). Consistent
with the lack in forming high-order oligomers, BAX C126S
variant was severely impaired in mitochondrial targeting. In
contrast to our biochemical approach, we detected in addition
to the cytosolic distribution an association of BAX C126S
with mitochondria via fluorescence microscopy (Figure 2d),
which was most likely due to the availability of endogenous
BAX WT in Cos7 cells. However, this interaction of EGFP-
BAX C126S with the MOM did not result in a focal
accumulation of EGFP-BAXC126S at mitochondrial sites, a
hallmark for apoptotic cell death,35,36 as it was observed for
EGFP-BAX WT and C62S (Figure 2d). In addition, the
mitochondrial morphology in Cos7 cells expressing EGFP-
BAXC126S was not altered and the membrane potential
remained unaffected, which was indicated by intact Mito-
Tracker staining. Similar to previous work,35 Cos7 cells
expressing EGFP-WT BAX or EGFP-BAX C62S showed
punctate fluorescence staining in B10% of EGFP-BAX-
expressing cells. In contrast, EGFP-BAX C126S showed
mostly diffuse localization in the cytosol and a significantly
reduced punctate staining (B2%).
To address the question whether S-palmitoylated BAX
specifically localizes to the mitochondria, we applied ABE
chemistry to identify BAX palmitoylation in different
subcellular fractions of HEK293 cells. S-palmitoylation of
endogenous BAX was high in fractions that were positive in
the mitochondrial marker (VDAC) but low in fractions
corresponding to the Golgi (1,4-galactosyltransferase-EGFP)
and endoplasmic reticulum (Calnexin) (Figure 2e). In
aggregate, all of our results suggest that S-palmitoylation of
Cys126 is crucial for BAX oligomerization and mitochondrial
targeting.
Functional significance of S-palmitoylated BAX.
High-level expression of BAX in mammalian cells induces
mitochondrial cytochrome c release, caspase activation and
apoptotic body formation.1 On the basis of our observation
that the BAX C126S variant is not processed to p18BAX
(Figure 2a), which is believed to accelerate stress-induced
apoptotic cell death,32 we determined the impact of Cys-126
in BAX-mediated apoptosis and analyzed apoptotic body
formation and caspase-3 activity in Cos7 and HEK293 cells.
The number of apoptotic Cos7 cells expressing BAX C126S-
MYC was significantly less than cells expressing WT or the
C62S BAX variant (Figures 3a and b). Accordingly, a
reduced caspase-3 activity was found with BAX C126S as
compared with WT and C62S BAX variant (Figure 3c).
Similar results for the apoptotic body formation were
obtained when EGFP-tagged variants were expressed in
Cos7 cells (Figure 3d), indicating that S-palmitoylation of
BAX at Cys-126 is important for the initiation of apoptosis.
Surprisingly, we found that MYC-tagged BAX exhibited a
higher potential to induce apoptosis compared with GFP-
BAX, which was mirrored by an increase in the total number
of apoptotic bodies in the respective cell cultures.
S-palmitoylation of BAX is mediated by specific DHHC
proteins. Protein S-palmitoylation is a frequent post-
translational modification in eukaroytic cells and mostly
mediated by members of the DHHC (Asp-His-His-Cys)
protein family.37 As palmitoylation occurs in a wide variety
of sequence contexts within soluble and transmembrane
proteins, S-palmitoylation is accommodated in mammalian
cells by a large array of enzymes.37 To establish whether
these proteins account for S-palmitoylation of BAX, we
recombinantly expressed human WT BAX and each of the
known 23 mouse DHHC proteins38 in HEK293 cells. After
16 h of coexpression, steady-state levels of BAX and
DHHC proteins were determined and BAX palmitoylation
was quantified using the ABE assay (Figure 4a and
Supplementary Figure 1). BAX palmitoylation was compared
with cells expressing BAX and GST as control. Twelve out of
23 DHHC proteins appeared to stimulate S-palmitoylation
of BAX. As expression levels of DHHC and BAX varied
between repeating experiments and since the relative
deviation between individual experiments (n¼ 7) strongly
influenced the calculation of statistical significance by the
t-test, certain DHHC proteins did not reach the threshold of
Po0.05. Only coexpression of BAX and DHHC enzymes 3,
7, 11, 12 or 21 significantly stimulated S-palmitoylation of
BAX as compared with control, suggesting that these DHHC
enzymes are able to palmitoylate BAX.
Does S-palmitoylation of BAX in turn accelerate onset of
apoptosis? To address this question, but to avoid stimulation
of apoptosis through BAX overexpression, we expressed
individual DHHC enzymes 3, 7, 11, 12 and 21 in HEK293 cells
and treated the cells 24 h later with the antagonistic BCL-2
ligand HA14-139 to induce apoptosis. Caspase-3 activities
were significantly elevated in cells expressing DHHC
enzymes 3, 7, 11, 12 and 21 as compared with mock-
transfected (GST expression) cells or cells expressing
DHHC13, which did not stimulate S-palmitoylation of BAX
(Figure 4b). In conclusion, transient expression of protein
S-palmitoylation of BAX
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acyltransferases mediating S-palmitoylation of BAX resulted
in an increased HA14-1-stimulated apoptosis.
S-palmitoylation of BAX is reduced in Hodgkin B cells.
Unlike in healthy individuals, B cells derived from patients
with Hodgkin disease resist the majority of anticancer
cytotoxic treatments based on the dysregulation of BAX
activation.30,40 However, the underlying molecular mechani-
sms causing defective BAX action still remain elusive. To
examine the impact of BAX S-palmitoylation on the observed
lack of BAX activation in theses tumor cell lines, we
examined the S-palmitoylation of BAX in protein extracts
from healthy (e.g. L1309) versus four independent,
previously described Hodgkin B-cell lines (L1236, L591,
L481 and KMH2).30 Although BAX expression levels were
comparable in all cells30 and the palmitoylation machinery
was found to be intact (Supplementary Figure 2), we observed
markedly reduced palmitoylation of BAX in Hodgkin B cells as
compared with control B cells (Figure 4c). Palmitoylation of
BAX thus clearly correlated with the previously reported lack
of BAX activity in Hodgkin B-cell lines.
Discussion
The proapoptotic BCL-2 protein BAX is a key regulator in the
intrinsic pathway of apoptosis, which critically influences the
onset of apoptotic cell death at the level of MOM integrity.
After induction of apoptosis, monomeric BAX is thought to
translocate from the cytosol to the mitochondria,41 where it
subsequently forms high-molecular-weight oligomers33,34 and
induces the permeabilization of MOM.42 Although many
studies elucidated distinct activation steps and discrete
conformational changes of BAX,43–46 there is still a lack in
understanding how BAX is redistributed to the mitochondria
and which processes facilitate the affinity of BAX for MOM.
The idea of an unidirectional redistribution in response to an
apoptotic stimulus is furthermore complicated by the observa-
tion that BAX can also be associated with MOMs in healthy,
non-apoptotic cells.47,48 Recent studies additionally proved
that in this case, BAX is not only localized in the cytosol or at
mitochondria, but exhibit a dynamic translocation behavior
between these two cellular compartments.6,18 Consequently,
such a shuttling mechanism highlights the requirement for a
dynamic and reversible biochemical process, which could act
as a molecular switch on the activity of BAX and therefore
account for the observed translocation cycles.
Our data highlight the S-palmitoylation of BAX as a possible
novel post-translational regulatory circuit, which orchestrates
BAX/mitochondria association and potentiates BAX proapop-
totic activity. Although our data for the palmitoylation of BAX
do not allow an unambiguous conclusion about the connection
between the modification and the activity of the BAX protein,
we are certain that the palmitoylation of BAX contributes to
the reported translocation cycles between the cytosol and
mitochondria.18
Notably, in a similar manner, a close relative of BAX, the
proapoptotic BCL-2 protein BID, has been previously shown
to be modified via N-myristoylation, a process that intimately
regulates its recruitment to MOM.20 Taken together, these
data underscore the critical role of lipid modifications as a
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molecular switch governing the mitochondrial association and
the proapoptotic action of BCL-2 proteins. BAX palmitoylation
may thus be as important for cell death signaling as
S-palmitoylation of CD95/Fas, which is required for receptor
clustering in the plasma membrane and targeting to lipid
membrane microdomains at an early step of apoptosis.49,50 At
this stage, it is not yet clear whether palmitoylation of BAX is
important for the dynamic regulation of membrane association
through the regulated addition and removal of palmitoyl
modifications as shown for proteins involved in intracellular
signaling cascades, such as H/NRas, G-protein subunit Gia,
PSD95 and GAP43, which can cycle between the plasma
membrane and multiple endosomal membranes.51 If constant
and fast cycles of palmitoylation and depalmitoylation are
presumed, one could expect that there should be no
palmitoylated BAX left at late time points after application of
2-BP. Nevertheless, the depalmitoylation of BAX is most likely
influenced by the accessibility of its modified Cys-126 to
palmitoyl protein thioesterases. Given that palmitoylated BAX
inserts into the outer mitochondrial membrane, the modified
Cys-126 is likely not accessible to the cytoplasmic environ-
ment and thus a depalmitoylation process would be unlikely to
occur. Hence, the turnover of the modification would be
significantly decreased and modified BAX detectable at late
time points after application of 2-BP.
Previous data showed that BAX can be cleaved (p18) by
cellular proteases including calpains during apoptotic and
non-apoptotic cell death.52 The previous data concerning the
proteolytic processing of BAX are so far not conclusively
addressing whether and how p18 BAX interferes with cell
death cascade. The elevated appearance of p18 in the C62S
variant of BAX in our experiments may be a result of an
increased accessibility of BAX for the responsible protease,
which is activated based on the cytotoxic activity of C62S BAX
variant. Intriguingly, C126S BAX induces less cytotoxicity and
the proteolytic processing of BAX in these cells is barely
detectable.
S-palmitoylation of membrane proteins has been proposed
(i) to occur most frequently in the proximity of their
transmembrane segments to affect their conformation, (ii) to
promote protein complex formation and (iii) to regulate their
association with cholesterol- and sphingolipid-rich membrane
domains.26 In line with these functions, we found that BAX is
palmitoylated at a position (Cys-126), which is located at the
C-terminal end of a transmembrane segment. Palmitoylation
also appeared to promote protein complex formation. As
mitochondria are known to maintain a specific sphingolipid
milieu53 to promote BAX activation,43 it will be interesting to
elucidate if palmitoylation targets BAX to sphingolipid mem-
brane microdomains, as described for other palmitoylated
membrane proteins.26
The site of BAX S-palmitoylation is located at the
C-terminal end of the a5-helix being adjacent to the short
positively charged loop Thr-127/Lys-128/Val129 connecting
a5 and a6.17,46 Both helices form a helical hairpin, which
inserts into the outer mitochondrial membrane at an early
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stage of apoptosis.34,54 Although no common consensus
sequences for S-palmitoylation has been identified yet, our
results fit well with in silico prediction of palmitoylation sites.55
It is intriguing to speculate that the palmitoyl group at position
Cys-126 promotes membrane targeting of helices a5 and a6 to
mitochondria and/or promotes their integration into the
lipid bilayer (Figure 5). However, whether palmitoylation of
Cys-126 induces tilting of the adjacent transmembrane
domains in the manner as predicted for other membrane
proteins56 remains to be determined.
Using the established recombinant expression approach,38
we identified five potential BAX-modifying DHHC proteins
(DHHC 3, 7, 11, 12 and 21), which were able to increase the
relative palmitoylation levels of BAX. Interestingly, we found
that upon expression of the respective DHHC proteins and
therefore increased BAX palmitoylation, cells were highly
sensitized toward apoptosis induction. In fact, after stimula-
tion of apoptosis, the DHHC-expressing cells responded with
a nearly twofold higher caspase-3 activity compared with
mock-transfected cells. Therefore, we could clearly demon-
strate a functional correlation between the relative palmitoyla-
tion level of BAX and the initiation of apoptosis.
All identified DHHC proteins are known to be localized at the
Golgi apparatus or the ER,57,58 which would implicate that
BAX must access those organelles to be modified. Although
it is well described that BAX can reside at both cellular
compartments,5,59 the connection between the palmitoylation
of BAX at the Golgi network or ER and the localization at the
MOM still needs to be elucidated.
The physiological impact of BAX palmitoylation was
validated by the analysis of HL-derived B cells, which proved
to be resistant to staurosporine-induced apoptosis.30 Notably,
this resistance was based on the inability to convert BAX to its
active state. Our analysis revealed that this insensitivity
against staurosporine is accompanied by a tremendous
reduction in the BAX palmitoylation levels compared with
control B-cell line L1309.
Taken together, our data suggest that S-palmitoylation of
BAX at Cys-126 represents a novel mechanism, which
facilitates mitochondrial targeting of BAX, its oligomerization
and BAX-mediated apoptosis. Consequently, the palmitoyla-
tion pathway of BAX identified in this work contributes to the
control of MOM permeabilization. Finally, our finding provides
a novel target to alter apoptosis in different cell types for the
treatment of malignant, autoimmune and infectious diseases.60
Materials and Methods
Plasmids. All human BAX constructs (Supplementary Table 1) used for
transfection of HEK293 and Cos7 cells were engineered by PCR and ligated into
pcDNA3.1(þ )myc-His (Invitrogen, Darmstadt, Germany) and pEGFP-C2
(Clontech, Heidelberg, Germany) vectors. BAX constructs used for baculovirus
infection of Sf9 cells were ligated into pVL1393 vector (BD Bioscience, Heidelberg,
Germany). The plasmids encoding mouse DHHC PATs (pEFBOS/HA-DHHCx,
x¼ 1–23) were a gift from Masaki Fukata (Okazaki, Japan).
Expression constructs and mutagenesis. The mammalian expression
plasmid pcDNA3.1 (þ )myc-His/BAX encoding human BAX was generated by
amplification of human BAX gene with HindIII and SfuI restriction sites and ligation into
pcDNA3.1(þ ) (Invitrogen), resulting in a C-terminal MYC/(6 )His-tagged protein.
The amplification was carried out in two steps to add a Kozak sequence before the
BAX coding region, to allow efficient protein expression of BAX. Residues Cys-62 and
Cys-126 of the human BAX gene were replaced with serine by fusion PCR using
human BAX as a template and the mutation primers C62S-fw/C62S-rev and C126S-
fw/C126S-rev, respectively (Supplementary Table 1). The fusion PCR products were
cloned with HindIII and SfuI restriction sites into pcDNA3.1(þ ). Pwo DNA polymerase
in combination with Taq polymerase was used in each PCR step. Generation of
recombinant baculovirus was carried out using baculovirus transfer vector pVL1393
(BD Bioscience). BAX was amplified by two separate PCRs using human BAX as
template and primers Sf9-fw/Sf9-rev (Supplementary Table 1) with an 30 extension
coding for a (6 )His-tag. Amplified DNA fragments were then ligated into pVL1393
between the SmaI and EcoRI restriction sites. Plasmids encoding GFP-tagged BAX
were generated by cloning WT BAX, BAXC62S and BAXC126S into the XhoI/SalI
sites of pEGFP-C2 (Clontech). To compensate a frameshift, an additional C was
added between the XhoI restriction site and the coding region of BAX. All plasmids
that were amplified by PCR were verified by DNA sequencing.
Preparation of mouse organs. Organs were obtained from adult mice,
washed with PBS, immediately frozen in liquid nitrogen, homogenized and stored
at  80 1C until further use.
I II III
C126
C62
Figure 5 Possible modes of S-palmitoylation-mediated BAX insertion into the outer mitochondrial membrane. BAX mitochondrial membrane insertion represents a key step in
apoptosis induction. Cys-126 of BAX becomes S-palmitoylated at the Golgi or at another endomembrane system by specific members of the DHHC protein acyltransferase family.
The palmitoyl moiety, once captured by the MOM, orients BAX at the surface of the mitochondrium and facilitates integration of helices a5 and a6 (II and III) into the membrane.
S-Palmitoylation of BAX may strongly favor formation of BAX dimers at the mitochondrial surface and subsequent assembly of higher order oligomers in the membrane. Both
processes are required for the formation of a pore for the release of mitochondrial proapoptotic proteins into the cytosol such as apoptosis-inducing factor (AIF), Smac/DIABLO and
cytochrome c. Both cysteines (Cys-62 and Cys-126) are highlighted in yellow. The palmitoyl moiety is marked in red. IMS, mitochondrial intermembrane space
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Cell cultures and treatments. HEK293 and Cos7 cells were cultured at
37 1C and 5% CO2 in Dulbecco’s modified Eagle’s medium, 10% fetal bovine
serum (FBS) and 2 mM glutamine. B-cell lines (L1309, L1236, KMH2, L428 and
L591) were cultured at 37 1C and 5% CO2 in RPMI 1640 medium, 10% FBS, 2 mM
glutamine, 100 IU/ml penicillin and 100mg/ml streptomycin. Sf9 cells were cultured
as suspension cultures in spinner flasks at 27 1C in modified Grace’s insect
medium (TNM-FH; AppliChem, Darmstadt, Germany), 10% FBS, 50 mg/ml
gentamicin and 2.5mg/ml amphotericin B. For high-level expression of WT and
mutant BAX, plasmids pcDNA3.1(þ )myc-His/BAX, pcDNA3.1(þ )myc-His/
BAXC62S or pcDNA3.1(þ )myc-His/BAXC126S (12.8mg cDNA/10 cm2 plate;
Supplementary Table 2) were transfected into HEK293 and Cos7 cells by using
polyethylenimine (Sigma, Munich, Germany) and FuGENE 6 (Roche, Mannheim,
Germany), respectively, for 16 h. For transfection of Sf9 cells, a baculovirus was
generated by co-transfection of pVL1393/BAX (1 mg cDNA/25 cm2 flask) and
BaculoGold DNA (0.25 mg) using Baculo Gold Transfection Buffer A and B
(BD Bioscience). Upon co-transfection, Sf9 cells synthesized BAX as well as
viable BAX-coding virus particles. The latter were used to transfect Sf9 cells for
large-scale production of BAX.
Acyl-biotinyl exchange assay. S-palmitoylation of protein was assessed
by the acyl-biotinyl exchange assay as described.31 Briefly, total protein extracts
(2 mg/ml) from mouse organs, cultured cells or purified mitochondria, Golgi and
endoplasmic reticulum were incubated for 3 h at 40 1C in solubilization
buffer containing 4% SDS, 1.7% Triton X-100, 5 mM EDTA, 20 mM methyl
methanethiosulfonate (MMTS), 50 mM Tris (pH 8.0) 1 protease inhibitor cocktail
(Roche). Then, MMTS was removed from the protein extract by means of
repeated chloroform–methanol precipitation. Protein pellets were solubilized in
SDS buffer containing 4% SDS, 5 mM EDTA, 50 mM Tris (pH 8.0) and
1 protease inhibitor. After clarifying by centrifugation, supernatants were split
into two and mixed with 0.2% Triton X-100, 0.4 mM n-[6-(biotinamido)hexyl]-
30-(20-pyridyldithio)-propionamide (HPDP-biotin; Thermo Scientific, Dreieich,
Germany), 5 mM EDTA and 1 protease inhibitor cocktail, respectively. One
sample was supplemented with 1 M hydroxylamine hydrochloride (pH 7.5). The
other sample contained no hydroxylamine but 50 mM Tris (pH 7.5). After 16 h of
incubation at 4 1C, protein of both samples was pelleted several times by
chloroform–methanol precipitation and resuspended in 4% SDS, 5 mM EDTA,
50 mM Tris (pH 8.0) and 1 protease inhibitor cocktail. Biotinylated proteins were
separated from non-biotinylated proteins by incubation with neutravidin agarose
beads (Thermo Scientific). After 16 h of incubation at 4 1C, the beads were
washed four times with PBS supplemented with 0.2% Triton X-100 and 0.1% SDS,
and bound proteins were eluted by incubation of beads with 2 SDS-PAGE
loading buffer at 98 1C for 5 min. Finally, samples were submitted to SDS-PAGE
and analyzed by immunoblotting with an anti-BAX antibody (BAX N-20; Santa
Cruz Biotechnology, Heidelberg, Germany).
Metabolic palmitoylation of BAX with 3H-palmitic acid. Sf9 cells
were infected with recombinant baculovirus containing the gene for C terminally
(6 )His-tagged human BAX (pVL1393/BAX). Forty-eight hours after infection,
Sf9 cells were incubated with 12 MBq/ml 3H-palmitic acid for 12 h. Cells were lysed
at 4 1C in 2% n-octyl-b-D-glucoside, 300 mM NaCl, 40 mM imidazole, 100 mM Tris
(pH 7.4) and EDTA-free protease inhibitor cocktail (Roche). After clarifying by
centrifugation, the supernatant was bound to Ni2þ -nitrilotriacetic resin (Qiagen,
Hilden, Germany). Specifically bound material was eluted with 300 mM NaCl,
500 mM imidazole, 100 mM Tris (pH 7.4) and submitted to non-reducing SDS-
PAGE. After fixation of the polyacrylamide gel in 40% methanol and 10% acetic
acid, the gel was incubated for 1.5 h in enhancer solution (Perkin-Elmer, Rodgau,
Germany), for 1 h in 5% PEG 6000, dried under vacuum on 3MM filter paper
(Whatman, Dassel, Germany) and analyzed by autoradiography.
Size-exclusion chromatography. HEK293 cells were harvested
12 h after transfection with pcDNA3.1(þ )myc-His/BAX, pcDNA3.1(þ )myc-
His/BAXC62S or pcDNA3.1(þ )myc-His/BAXC126S, washed with PBS and lysed
in 2% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate),
300 mM NaCl, 5 mM EDTA, 100 mM Tris (pH 8.0) and protease inhibitor cocktail.
After clarifying by centrifugation, protein extracts (5 mg) were loaded onto a
Superdex 200 16/60 size-exclusion column (GE Healthcare, Freiburg, Germany)
equilibrated with 300 mM NaCl, 1 mM MgCl2, 100 mM Tris (pH 8.0) and eluted at a
flow rate of 1 ml/min at 4 1C. Individual fractions were analyzed by SDS-PAGE and
immunoblotting. Molecular masses were determined using UV spectra of
chromatographs of thyroglobulin (669 kDa), apoferritin (443 kDa), ovalbumin
(44 kDa) and Smac/Diabolo (25 kDa) as protein standards.
Caspase-3 activity measurements. HEK293 cells transfected with
pcDNA3.1(þ )myc-His/BAX, pcDNA3.1(þ )myc-His/BAXC62S or pcDNA3.1(þ )
myc-His/BAXC126S were harvested 16 h after transfection and lysed by short
sonication (3 s) in ice-cold buffer containing 1% Triton X-100, 130 mM NaCl,
10 mM Na-pyrophosphate, 10 mM Tris and 10 mM NaH2PO4/Na2HPO4 (pH 7.5).
Equivalent amounts of protein were added to a reaction buffer containing 20mM
N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC), 10%
glycerol, 2 mM dithiothreitol and 20 mM HEPES pH 7.5). After incubation at
37 1C for 2 h, caspase-3 activities were measured by monitoring the release
of amino-4-methylcoumarin from Ac-DEVD-AMC using an Infinite 200 PRO
mircoplate reader (Tecan, Crailsheim, Germany). Amino-4-methylcoumarin was
excited at 380 nm. Fluorescence emission was recorded at 460 nm with an
integration time of 20ms. The band widths for excitation and emission were 9 and
20 nm, respectively.
Subcellular localization, confocal fluorescence microscopy and
visual assessment of apoptotic cell death. Cos-7 cells were plated on
collagen-coated glass coverslips and grown for 48 h. Subsequently, the Cos7 cells
were transfected with pEGFP-C2/BAX, pEGFP-C2/BAXC62S or pEGFP-
C2/BAXC126S and 16 h after transfection incubated with a mitochondrion-specific
dye (75 nM MitoTrackerRed CMXRos; Invitrogen) at 37 1C for 1 h. Cells were fixed
with 4% paraformaldehyde in PBS for 20 min, quenched in 50 mM NH4Cl2 for
20 min and incubated with PBS containing DNA-specific dye (1 mg/ml
bisbenzimide; Applichem). After three additional PBS washing steps, the cover
slips were washed with water and mounted with Mowiol containing
1,4-diazobicyclo-[2.2.2]-octane (Sigma). Images were recorded with an AZ-C2þ
confocal laser scanning microscope using a 60/1.4 Plan Apo oil immersion
objective (Nikon, Du¨sseldorf, Germany). Fluorescent dyes/proteins were excited at
a wavelength of 388 nm (bisbenzimide), 488 nm (MitoTrackerRed) and 568 nm
(EGFP). Alternatively, HEK293 cells were transfected with pcDNA3.1(þ )myc-His/
BAX, pcDNA3.1(þ )myc-His/BAXC62S and pcDNA3.1(þ )myc-His/BAXC126S.
Sixteen hours after transfection, mitochondria, Golgi and endoplasmic reticulum
were isolated and analyzed by SDS-PAGE and immunoblotted with the indicated
antibodies according to standard procedures. Apoptotic cell death was measured
by counting the number of cells revealing apoptotic bodies.
Statistics. Statistical analyses were carried out using Student’s t-test.
P-valueso0.05 were considered significant.
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